Related Experiment Video
Updated: Jun 18, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United
Umang Swami1, Agnes Hong2, Brandon Diessner3
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA.
Abstract:
Aim: Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.Patients & methods: This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.Results: Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.Conclusion: Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.
Related Concept Videos
Cancer Survival Analysis
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

